Search results
Added:
1 month ago
Added:
4 weeks ago
Added:
2 months ago
AHA Scientific Sessions 2025 - Phase 1 results show the CRISPR-Cas9 gene editing therapy is a safe treatment option targeting ANGPTL3 in patients with lipid disorders.Prof Stephen Nicholls (Monash Victorian Heart Institute, Clayton, AU) joins us to share results from a first-in-human phase 1 trial investigating a one-time infusion of CTX310, a CRISPR-Cas9 gene editing therapy, at different doses…
View more
Added:
1 year ago
ECO 2024 — Dr Riccardo Panella (Aalborg University, DK) joins us to discuss a ncRNA-based approach in treating obesity. This new combinatory treatment (Resalis) aims to increase GLP1-RA efficacy by targeting non-coding RNA.Questions1. What is the background of this combinatory approach?2. What data did you present at ERA 24?3. What are the challenges and opportunities in approaching combinatory…
View more
Added:
2 years ago
AHA 2023 — Investigator, Dr Steven E Nissen (Cleveland Clinic, US) is interviewed by CardioNerds Medical Education Fellow, Dr Maryam Barkhordarian (HMH Palisades Medical Center, US) on the trial that assessed the efficacy and safety of lepodisiran, a small interfering RNA (NCT05565742).The main purpose of this phase 2, randomised, double-blind, placebo-controlled study (Eli Lilly and Company) is…
View more
Added:
8 months ago
EuroPCR 25 - 10-year outcomes from DANAMI-3-PRIMULTI show FFR-guided complete revascularisation in ST-elevation myocardial infarction (STEMI) reduces the risk of future events. We are joined by Dr Thomas Engstrøm (University of Copenhagen, Copenhagen, Denmark) to discuss 10-year outcomes from the multicenter, randomized DANAMI-3-PRIMULTI trial investigating FFR-guided complete…
View more
Added:
2 months ago
TCT 2025 - The randomized VICTORY Study finds OCT-guided PCI involving lesion preparation with the OPN super-high-pressure non-compliant balloon is non-inferior to intravascular lithotropsy.Dr Matthias Bossard (Kantonsspital Lucerne, Lucerne, CH) joins us to discuss findings from the VICTORY Trial, a randomized, multicenter, non-inferiority comparison evaluating intravascular lithotripsy versus…
View more
Added:
1 year ago
TCT Conference 2024 - Significant reduction in TLF and TVF and flattening of event curves after 6 months in favour of DynamX Bioadaptor.Dr David Erlinge (Skane University Hospital, Lund, SE) joins us onsite at TCT Conference to discuss the findings from INFINITY-SWEDEHEART (NCT04562805).INFINITY-SWEDEHEART is a prospective, multicenter, randomized registry-based clinical trial, where patients…
View more
Added:
2 years ago
ESC 24: The OCCUPI Trial
Added:
1 year ago
Video